Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - poliomyelitis virus type 1; poliomyelitis virus type 1; poliomyelitis virus type 3 - suspension - poliomyelitis virus type 3 nlt 10^6.0 ccid50; poliomyelitis virus type 1 nlt 10^5.8 ccid50; poliomyelitis virus type 1 nlt 10^6.0 ccid50 - poliomyelitis oral, monovalent live attenuated - active immunisation against poliomyelitis infection caused by types 1 and 3 poliomyelitis viruses at any age after receiving at least one dose of ipv.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - polio virus type 1 inactivated, polio virus type 2 inactivated, polio virus type 3 inactivated - suspension for injection - %v/v - poliomyelitis vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - polio virus type 1 inactivated, polio virus type 2 inactivated, polio virus type 3 inactivated - suspension for injection - %v/v - poliomyelitis vaccines

Kenya - English - Pharmacy and Poisons Board

polio trivalent bulk - suspension for injection - inactivated poliomyelitis virus type 1,… - poliomyelitis trivalent inactivated whole virus

Israel - English - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - suspension for injection - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 4 years and over as a booster following primary immunisation.adacel polio is not indicated for primary immunisation. adacel polio is not indicated for treating diseases caused by b.pertussis, c.diphtheriae or c.tetani or by poliomyelitis infections

Israel - English - Ministry of Health

sanofi israel ltd - poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated - suspension for injection - poliovirus type 1 inactivated 40 u/vial; poliovirus type 2 inactivated 8 u/vial; poliovirus type 3 inactivated 32 u/vial - poliomyelitis vaccines - prophylaxis of poliomyelitis.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - poliovirus type 1 (live, attenuated) - oral suspension - poliomyelitis virus - poliomyelitis oral, monovalent, live attenuated

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - poliovirus type 3 (live, attenuated) - oral suspension - poliomyelitis virus - poliomyelitis oral, monovalent, live attenuated

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - poliovirus type 1 (live, attenuated) ; poliovirus type 2 (live, attenuated) ; poliovirus type 3 (live, attenuated) - oral suspension - poliomyelitis virus - poliomyelitis oral, trivalent, live attenuated

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - poliovirus type 2 (live, attenuated) ; poliovirus type 3 (live, attenuated) ; poliovirus type 1 (live, attenuated) - oral suspension - poliomyelitis virus - poliomyelitis oral, trivalent, live attenuated